HIV coinfection with hepatitis c
|
Hepatitis C |
|
Diagnosis |
|
Treatment |
|
HIV coinfection with hepatitis c On the Web |
|
American Roentgen Ray Society Images of HIV coinfection with hepatitis c |
|
Risk calculators and risk factors for HIV coinfection with hepatitis c |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Varun Kumar, M.B.B.S. [2]
Recommendations for Diagnosis and Treatment of Persons with HIV Coinfection: AASLD Practice Guidelines 2009[1]
| “ |
1. Anti-HCV testing should be performed in all HIV-infected persons (Class I, Level B). 2. HCV RNA testing should be performed to confirm HCV infection in HIV-infected persons who are positive for anti-HCV, as well as in those who are negative and have evidence of unexplained liver disease (Class I, Level B). 3. Hepatitis C should be treated in the HIV/HCV co-infected patient in whom the likelihood of serious liver disease and a treatment response are judged to outweigh the risk of morbidity from the adverse effects of therapy (Class I, Level A). 4. Initial treatment of hepatitis C in most HIV infected patients should be peginterferon alfa plus ribavirin for 48 weeks at doses recommended for HCV mono-infected patients (Class I, Level A). 5. When possible, patients receiving zidovudine (AZT) and especially didanosine (ddI) should be switched to an equivalent antiretroviral agent before beginning therapy with ribavirin (Class I, Level C). 6. HIV-infected patients with decompensated liver disease (CTP Class B or C) should not be treated with peginterferon alfa and ribavirin and may be candidates for liver transplantation (Class IIa, Level C). |
” |
References
- ↑ Swan T, Curry J (2009). "Comment on the updated AASLD practice guidelines for the diagnosis, management, and treatment of hepatitis C: treating active drug users". Hepatology (Baltimore, Md.). 50 (1): 323–4, author reply 324–5. doi:10.1002/hep.23077. PMID 19554546. Retrieved 2012-02-21. Unknown parameter
|month=ignored (help)